SENATE RULES COMMITTEE

Office of Senate Floor Analyses

(916) 651-1520 Fax: (916) 327-4478

UNFINISHED BUSINESS

Bill No: SB 306

Author: Pan (D), et al.

Amended: 9/7/21 Vote: 2.1

SENATE HEALTH COMMITTEE: 9-1, 4/7/21

AYES: Pan, Eggman, Gonzalez, Hurtado, Leyva, Limón, Roth, Rubio, Wiener

NOES: Grove

NO VOTE RECORDED: Melendez

SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 10-3, 4/19/21

AYES: Roth, Archuleta, Becker, Dodd, Eggman, Hurtado, Leyva, Min, Newman,

Pan

NOES: Bates, Jones, Ochoa Bogh NO VOTE RECORDED: Melendez

SENATE APPROPRIATIONS COMMITTEE: 5-2, 5/20/21 AYES: Portantino, Bradford, Kamlager, Laird, Wieckowski

NOES: Bates, Jones

SENATE FLOOR: 31-7, 6/2/21

AYES: Allen, Archuleta, Atkins, Becker, Bradford, Caballero, Cortese, Dodd, Durazo, Eggman, Glazer, Gonzalez, Hertzberg, Hueso, Hurtado, Kamlager, Laird, Leyva, Limón, McGuire, Min, Newman, Pan, Portantino, Roth, Rubio,

Skinner, Stern, Umberg, Wieckowski, Wiener

NOES: Bates, Borgeas, Dahle, Grove, Jones, Ochoa Bogh, Wilk

NO VOTE RECORDED: Melendez, Nielsen

ASSEMBLY FLOOR: 56-8, 9/10/21 (ROLL CALL NOT AVAILABLE)

SUBJECT: Sexually transmitted disease: testing

SOURCE: APLA Health

Black Women for Wellness Action Project

Essential Access Health Fresno Barrios Unidos Los Angeles LGBT Center San Francisco AIDS Foundation

DIGEST: This bill (1) permits pharmacists to dispense a drug, without the name of an individual for whom the drug is intended, when prescribed for the sexual partner of someone who has been diagnosed with a sexually transmitted disease (STD); (2) prohibits health care providers who prescribe, dispense, or furnish such a drug from being subject to, civil, criminal, or administrative penalties, as specified; (3) requires a syphilis blood test, during the third trimester of pregnancy and at delivery, as specified; (4) requires public and commercial health coverage of home STD test kits; and (5) adds rapid STD tests to existing law which permits HIV counselors to perform rapid HIV and hepatitis C tests.

Assembly Amendments:

- 1) Delete provisions that would have required Family PACT reimbursement for STD services provided to patients who are not at risk for experiencing or causing an unintended pregnancy, and who are not in need of contraceptive services;
- 2) Clarify that Medi-Cal is required to pay for home STD kits and EPT therapy only to the extent that federal approval is received;
- 3) Grant CDPH authority to determine which HIV, HCV, and STD test will be included in the training for HIV counseling staff;
- 4) Correct a drafting error to ensure that HIV counselors are only allowed to perform an HIV, HCV, or STD test if they have been trained and demonstrated proficiency in administering the test AND to ensure that HIV counselors demonstrates sufficient knowledge of HIV, HCV, and STDs to provide appropriate counseling and referrals to patients;
- 5) Revise the definition of "home STD kit;" and,
- 6) Make technical, clarifying changes.

ANALYSIS:

Existing law:

- 1) Permits physicians, nurse practitioners, certified nurse-midwives, and physician assistants who diagnose an STD to prescribe, dispense, furnish, or otherwise provide prescription antibiotic drugs to that patient's sexual partner or partners without examination of that patient's partners (referred to as "expedited partner therapy" or "EPT"). [HSC §120582]
- 2) Requires physicians and or other persons engaged in prenatal care of a pregnant woman, or attending the woman at delivery, to obtain a syphilis blood test at the time of the first professional visit or within ten days. [HSC §120685]
- 3) Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); and the California Department of Insurance (CDI) to regulate health and other insurance. [HSC §1340, et seq., INS §106, et seq.]
- 4) Establishes the Department of Health Care Services (DHCS) to administer the Medi-Cal program, which provides medical coverage to low income persons, and the Family PACT program, which provides comprehensive clinical family planning services to low income persons. [WIC §14000, et seq., WIC §14132, et seq.]
- 5) Establishes the State-Only Family Planning Program to provide family planning services for men and women, including emergency and complication services directly related to the contraceptive method and follow-up, and consultation and referral services. [WIC §24007]
- 6) Permits HIV counselors to perform HIV, hepatitis C virus (HCV), or combination HIV/HCV tests that are waived under the federal Clinical Laboratory Improvement Act (CLIA) under certain circumstances, including if they are working under the direction of a physician and are trained in accordance with specified state and federal guidelines. Requires these HIV counselors to be either trained by California Department of Public Health's (CDPH's) Office of AIDS (OA) and working in an HIV counseling and testing site funded by CDPH through a local health department (LHD), or to be working in an HIV counseling and testing site that utilizes HIV counseling staff who are trained by the OA and are approved by an LHD. [HSC §120917]

This bill:

- 1) Requires health care providers who prescribe, dispense, or otherwise furnish EPT, and are unable to obtain the name of a patient's sexual partner, to include the words "expedited partner therapy" or the letters "EPT" on the prescription.
- 2) Permits pharmacists to dispense a drug prescribed under EPT and to label the drug without the name of an individual for whom the drug is intended, if the prescription includes "expedited partner therapy" or "EPT."
- 3) Prohibits a pharmacist or other health care provider who prescribes, dispenses, furnishes, or otherwise renders EPT, from being liable in, or subject to, a civil, criminal, or administrative action, sanction, or penalty for rendering EPT, if the use of EPT is in compliance with this bill and existing law, except in cases of intentional misconduct, gross negligence, or wanton or reckless activity.
- 4) Requires health care professionals engaged in providing prenatal care or attending a birthing patient at the time of delivery to provide syphilis screening and testing as outlined in the most recent guidelines published by CDPH. Prohibits this bill from limiting a LHD's ability to provide additional recommendations or guidelines for syphilis screening and testing, or from limiting the ability of a health care professional to follow screening and testing recommendations or guidelines issued by local health authorities, as long as, at minimum, the health care professional complies with CDPH guidelines.
- 5) Requires Family PACT, the State-Only Family Planning Program, Medi-Cal, and commercial health plans and health insurers to cover home STD test kits that are deemed medically necessary or appropriate and ordered by a clinician, as specified.
- 6) Adds CLIA-waived (rapid) STD tests to existing law which permits HIV counselors to perform rapid HIV/HCV tests. Requires HIV counselors that perform any of these tests to complete an HIV counseling training course that has been approved by CDPH OA. Prohibits HIV counselors from administering a rapid HIV, HCV, or STD test until they demonstrate proficiency in administering the test.
- 7) Requires HIV counselors to demonstrate sufficient knowledge of HIV, HCV, and STDs to provide appropriate counseling and referrals to patients. Requires HIV counselors certified prior to January 1, 2022, who will administer rapid STD tests, to obtain training described in 6) above. Prohibits HIV counselors

from performing rapid STD tests until after completing the required training, unless they are also certified as a limited phlebotomist technician.

8) Makes other technical, clarifying changes to existing law.

Background

- 1) Centers for Disease Control and Prevention data. The Centers for Disease Control and Prevention (CDC) estimates that one in five people in the U.S. have an STD. In 2018, nearly 68 million STD infections were reported nationwide, and rates of syphilis, chlamydia, or gonorrhea are up 40% since 2013. California had the second highest syphilis rates in the nation in 2018. Between 2008 and 2018, the syphilis rate among women of reproductive age increased by 743%. In 2018, more than 329 babies were born with congenital syphilis in California and there were 20 stillbirths associated with the disease. Last year, the CDC announced that a new, antibiotic-resistant strain of gonorrhea began to spread across the country amidst the COVID-19 crisis. A December 2020 CDPH alert about the rising number of gonococcal infections warned of a severe complication of untreated gonorrhea that spreads across the body through the bloodstream. The CDC estimates that untreated STDs cause at least 24,000 women in the U.S. each year to become infertile. Untreated syphilis can also lead to negative maternal child health outcomes, including infant deaths. The CDC estimates that of pregnant women who acquire syphilis up to four years before delivery, 80% will transmit the infection to the fetus, and 40% may result in stillbirth or death.
- 2) *Inequities persist*. The STD crisis affects communities across the state, but California youth, people of color, and gay, bisexual, and transgender people are disproportionately impacted. Statewide data indicate over half of all STDs in the state are experienced among California youth ages 15 to 24 years old. African Americans are 500% more likely to contract gonorrhea and chlamydia than their white counterparts. These disparities are expected to worsen as a result of the COVID-19 pandemic. CDC studies suggest a range of factors may contribute to rising STD rates, including inequitable access to health care and culturally competent medical services, race, poverty, stigma, discrimination, and drug use.

According to a California Health Benefits Review Program (CHBRP) analysis of this bill, despite broad recommendations for STD screening among target populations and expanded screening over the past 20 years, data indicate that there is vast room for improvement. A national STD survey of youth (ages 15 to 25) years found very few received recommended screening for STDs — only

- 16.6% of females and 6.6% of males had been tested within the last year. A 2017 study found that delayed HIV diagnoses among high-risk populations (e.g., men who have sex with men (MSM), sex partners of persons with HIV infection, etc.) continued to be substantial due to missed screening opportunities. In fact, a majority of patients at high risk for HIV (75%) reported not being offered an HIV test during their primary care visit within the last 12 months.
- 3) Costs of the STD crisis. The CDC estimates that STD infections acquired in 2018 totaled nearly \$16 billion in direct lifetime medical costs nationwide. Chlamydia, gonorrhea, and syphilis accounted for more than \$1 billion of the total cost. Sexually acquired HIV and human papilloma virus (HPV) were the costliest due to lifetime treatment for HIV at \$13.7 billion and treatment for HPV-related cancers at \$755 million. Approximately \$1 billion is spent annually in California on health costs associated with STDs.
- 4) Congenital syphilis. According to a July 2020 article in Health Affairs, as the health care system responds to COVID-19 cases across the country, a June 2020 CDC analysis reminds us that there's another, often overlooked, epidemic that doesn't show signs of slowing down: STDs. The most unexpected finding is the alarming rise in congenital syphilis, which occurs when the infection is passed from mother to baby during pregnancy. Recent data show that cases of congenital syphilis increased 40% between 2017 and 2018, from 24 to 33 cases per 100,000 live births. While these increases are being seen across the country, the western and southern regions of the U.S. have been hit particularly hard. According to a 2019 California HealthCare Foundation report, Texas, Nevada, Louisiana, Arizona, and California had the highest rates of congenital syphilis in 2018. According to CDPH, in California in 2018, 329 babies with congenital syphilis were reported, representing a 900% increase from 2012. According to the 2020 CDC analysis, half of the cases of congenital syphilis occur due to gaps in testing and treatment during prenatal care. The CDC recommends testing for syphilis for all pregnant women in the first prenatal visit and retesting in the third trimester for women who are at high risk for syphilis, who live in areas with high numbers of syphilis cases, and/or who were not previously tested, or had a positive test in the first trimester. CDPH guidance on syphilis testing states, in part, that all pregnant patients should be screened for syphilis at least twice during pregnancy: once at either confirmation of pregnancy or at the first prenatal encounter (ideally during the first trimester) – and again during the third trimester (ideally between 28–32 weeks' gestation), regardless of whether such testing was performed or offered during the first two trimesters. CDPH guidance also states that patients should be screened for

- syphilis at delivery, except those at low risk who have a documented negative screen in the third trimester.
- 5) EPT. According to the CDC, effective clinical management of patients with treatable STDs requires treatment of the patients' current sex partners to prevent reinfection and curtail further transmission. The standard approach to partner treatment includes clinical evaluation in a health care setting, with partner notification by the presenting patient, by the provider, or by both. Provider-assisted referral for follow-up care is considered the optimal strategy for partner treatment, but is not always feasible. The CDC states that EPT is a useful option to facilitate partner treatment, particularly for treatment of male partners of women with chlamydial infection or gonorrhea. According to a May 2020 analysis, EPT is explicitly permitted in 45 states, is potentially allowable in four states (Alabama, Kansas, Oklahoma, and South Dakota), and prohibited in South Carolina.
- 6) Home STD kits. According to the CHBRP report of this bill, most home STD kits are "home-to-lab," except for CLIA-waived, rapid tests. For non-rapid tests, a specimen is self-collected at home using materials and instructions provided in the kit and the kit is then mailed to a laboratory or medical facility for processing and diagnosis. When self-collected in a setting outside of a medical setting, collection of specimens may not be covered by Federal Drug Administration (FDA) clearance. In order for a home collection kit to be FDA approved or cleared, it would have to be established that the results of the diagnostic tests are equivalent to a self-collected sample obtained in a clinical environment. Establishing such equivalency can be costly and it has not been done for all available kits. STD home test kits that are marketed directly to the consumer often refer to using "FDA-approved processes," a phrase that references use of approved laboratory processes for the processing of the specimen — not self-collection in a nonclinical setting. The source of the approval can also take more than one form. While some home-to-lab kits state that they follow FDA-approved processes for processing and diagnosis, others note only that the labs that will be processing the specimens are certified by CLIA.

Comments

Author's statement. According to the author, California has taken a robust approach to expanding access to health care. However, the state has lagged in enacting comprehensive policies to increase access to STD screening and treatment, and uninsured Californians lack a pathway to STD treatment. For

example, California's EPT statute, the first in the nation, permits health care providers to treat the sex partners of patients diagnosed with STDs by providing prescriptions or medications to the patient to take to his/her partner without the health care provider first examining the partner. However, our EPT statute is underutilized because it lacks liability protections for providers who might otherwise be interested in integrating the evidence-based practice into their service delivery. HIV Counselors, trained professionals working with some of our most vulnerable populations, can provide rapid testing for HIV and hepatitis, but cannot perform rapid tests for other common STDs. Current law requires congenital syphilis screening in the first trimester of pregnancy, but without additional screening requirements, far too many cases go undetected. Finally, during the pandemic, with undiagnosed cases of STDs rampant, access to home test kits, which would detect undiagnosed STDs, is limited due to coverage restrictions. The COVID-19 pandemic has exacerbated STD infection rates across the country, and this bill takes a comprehensive approach to address California's STD crisis by expanding access to STD care in an equitable way.

Related/Prior Legislation

SB 855 (Pan, 2020) would have permitted the Family PACT program to offer covered benefits to income-eligible patients, even if contraception is not discussed during the patient encounter, updated California's EPT statute to include provider liability protections used in other states, and clarified that Medi-Cal managed care enrollees can obtain STD services from their provider of choice. SB 855 was not heard in the Senate Business, Professions, and Economic Development Committee.

SB 932 (Wiener, 2020) would have added rapid STD tests to existing law which permits HIV counselors to perform rapid HIV/HCV tests. These provisions were amended out of the bill.

FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes

According to the Assembly Appropriations Committee, amendments recently taken significantly narrow this bill, reducing costs. Estimates for the remaining provisions are uncertain but could range from several hundred thousand dollars to more than \$1 million (50% state General Fund and 50% federal funds).

SUPPORT: (Verified 9/10/21)

APLA Health (co-source)
Black Women for Wellness Action Project (co-source)
Essential Access Health (co-source)

Fresno Barrios Unidos (co-source)

Los Angeles LGBT Center (co-source)

San Francisco AIDS Foundation (co-source)

ACCE Action

Access Reproductive Justice

Access Support Network

AIDS Healthcare Foundation

Alliance of Californians for Community Empowerment Action

American Academy of Pediatrics, California

American Nurses Association California

Bienestar Human Services

Biocom California

Black Women for Wellness Action Project

Buen Vecino

Business & Professional Women of Nevada County

California Black Health Network

California Hepatitis Alliance

California Latinas for Reproductive Justice

California LGBTQ Health and Human Services Network

California Life Sciences Association

California Nurse-Midwives Association

California Pharmacists Association

California Physicians Alliance

California Society of Health-System Pharmacists

California State Board of Pharmacy

California Women's Law Center

CaliforniaHealth+ Advocates

Citizens for Choice

Community Clinic Association of Los Angeles County

County Health Executives Association of California

Courage California

Desert AIDS Project

End HEP C SF

Essential Access Health

Fresno Barrios Unidos

Harm Reduction Coalition

Harm Reduction Services

HIVE

Los Angeles LGBT Center

MPact/Fijate Bien Program

NARAL Pro-Choice California

National Coalition of STD Directors
National Health Law Program
Plan C
Planned Parenthood Affiliates of California
Religious Coalition for Reproductive Choice California
Sacramento LGBT Community Center
San Francisco Aids Foundation
Team Lily
The Los Angeles Trust for Children's Health
The Source LGBT+ Center
Via Care Community Health Center
Western Center on Law & Poverty, Inc.
Women's Foundation California
Women's Health Specialists
One individual

OPPOSITION: (Verified 9/10/21)

America's Health Insurance Plans Association of California Life and Health Insurance Companies California Association of Health Plans California Chamber of Commerce Department of Finance

arguments In Support: The sponsors of this bill write that the STD epidemic requires a bold response and that California must take a comprehensive and robust approach to strengthening our public health infrastructure and expanding access to STD coverage and care to communities most impacted by the STD crisis. Supporters state that the COVID-19 pandemic has exacerbated STD rates in California and across the country that were already skyrocketing to epidemic proportions prior to the public health emergency. Nearly 340,000 Californians were infected with syphilis, chlamydia, or gonorrhea in 2018 – up 40% since 2013. In 2016 alone, gonorrhea rates increased by double digits in the following counties: Sacramento 50%, Los Angeles 27%, San Diego 35.5%, San Francisco 18%, and Kings 41%. Untreated STDs can lead to serious long-term health consequences, including infertility, blindness in the case of gonorrhea, cervical cancer related to HPV infections, and negative maternal and child health outcomes. STDs also increase both the transmission and acquisition of HIV.

ARGUMENTS IN OPPOSITION: The America's Health Insurance Plans, the Association of California Life and Health Insurance Companies, and the California Association of Health Plans, writing in opposition to a number of mandate bills,

state that California has been a national leader in maintaining a stable market despite rising costs and uncertainty at the federal level over the individual and employer market. The COVID-19 pandemic has forced us all to re-evaluate our priorities this year, focusing on the critical issues necessary to address this pandemic. Now is not the time to inhibit competition with proscriptive mandates that reduce choice and increase costs. In the face of this continued uncertainty and efforts to fragment the market and promote less comprehensive coverage, California needs to protect the coverage gains we've made and stay focused on the stability and long-term affordability of our health care system. Benefit mandates impose a one-size-fits-all approach to medical care and benefit design driven by the legislature, rather than consumer choice. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. State mandates increase costs of coverage – especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates.

Prepared by: Melanie Moreno / HEALTH / (916) 651-4111 9/10/21 19:27:15

**** END ****